Explicyte will be attending the AACR Virtual Annual Meeting 2020 and will present new results from its collaborative work with Domain Therapeutics on the GPCRome modulation in the context of cancer immunotherapy.
Anti-angiogenic therapy combination with hypoxia-regulating agent leads to improved tumor regression
We will be attending the AACR Virtual Annual Meeting, from June 22 to 24, 2020 to present our posters featuring our capacities / platforms that support drug discovery in Immuno-Oncology.
We will be attending the AACR Virtual Annual Meeting, from June 22 to 24, 2020 to present our posters featuring our capacities / platforms that support drug discovery in Immuno-Oncology.
Explicyte’s expertise and advanced technologies have been harnessed so as to build a cell-based service platform for immuno-oncology (IO) assessment and drug discovery.
New explicyte publication in Frontiers in Immunology!
B cells are to the forefront of cancer immunotherapy. Discover how!
How about an opportunity to assess your compounds in a comprehensive and cost-effective manner? Explicyte is planning a new in vivo shuttle session by mid March, to be held on a series of either subcutaneously- or orthotopically-inoculated syngeneic tumor mouse models.
We will be attending the ESMO Immuno-Oncology Congress in Geneva, from December 11 to 14, 2019. We are glad to take this opportunity to meet you there, describe our service offerings and approach your research projects.
See our case study or download our white paper!
Explicyte is planning a new in vivo shuttle session by mid-November that can be held on a series of syngeneic tumor mouse models. This shuttle session can focus either on only an in vivo efficacy monitoring or on a comprehensive assessment relying on a multiparametric platform strategy for a deeper understanding of how a cancer therapy performs.
Immunotherapy-based anti-cancer strategies such as immune checkpoint inhibitors promote antitumor immune response driven by themobilization of effector immune cell activity and/or reversal of immunosuppressive mechanisms.
Explicyte was pleased to participate in the AACR Virtual Annual Meeting to get breakthroughs in Immuno-Oncology and to present our posters featuring our capacities that support drug discovery.